These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
179 related articles for article (PubMed ID: 29650037)
1. Open-label, randomized multicentre phase II study to assess the efficacy and tolerability of sunitinib by dose administration regimen (dose modification or dose interruptions) in patients with advanced or metastatic renal cell carcinoma: study protocol of the SURF trial. Mouillet G; Paillard MJ; Maurina T; Vernerey D; Nguyen Tan Hon T; Almotlak H; Stein U; Calcagno F; Berthod D; Robert E; Meurisse A; Thiery-Vuillemin A Trials; 2018 Apr; 19(1):221. PubMed ID: 29650037 [TBL] [Abstract][Full Text] [Related]
2. Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma. Escudier B; Roigas J; Gillessen S; Harmenberg U; Srinivas S; Mulder SF; Fountzilas G; Peschel C; Flodgren P; Maneval EC; Chen I; Vogelzang NJ J Clin Oncol; 2009 Sep; 27(25):4068-75. PubMed ID: 19652072 [TBL] [Abstract][Full Text] [Related]
3. Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib: The SURTIME Randomized Clinical Trial. Bex A; Mulders P; Jewett M; Wagstaff J; van Thienen JV; Blank CU; van Velthoven R; Del Pilar Laguna M; Wood L; van Melick HHE; Aarts MJ; Lattouf JB; Powles T; de Jong Md PhD IJ; Rottey S; Tombal B; Marreaud S; Collette S; Collette L; Haanen J JAMA Oncol; 2019 Feb; 5(2):164-170. PubMed ID: 30543350 [TBL] [Abstract][Full Text] [Related]
4. Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial. Powles T; Plimack ER; Soulières D; Waddell T; Stus V; Gafanov R; Nosov D; Pouliot F; Melichar B; Vynnychenko I; Azevedo SJ; Borchiellini D; McDermott RS; Bedke J; Tamada S; Yin L; Chen M; Molife LR; Atkins MB; Rini BI Lancet Oncol; 2020 Dec; 21(12):1563-1573. PubMed ID: 33284113 [TBL] [Abstract][Full Text] [Related]
5. Anlotinib Versus Sunitinib as First-Line Treatment for Metastatic Renal Cell Carcinoma: A Randomized Phase II Clinical Trial. Zhou AP; Bai Y; Song Y; Luo H; Ren XB; Wang X; Shi B; Fu C; Cheng Y; Liu J; Qin S; Li J; Li H; Bai X; Ye D; Wang J; Ma J Oncologist; 2019 Aug; 24(8):e702-e708. PubMed ID: 30902918 [TBL] [Abstract][Full Text] [Related]
6. Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. Haas NB; Manola J; Uzzo RG; Flaherty KT; Wood CG; Kane C; Jewett M; Dutcher JP; Atkins MB; Pins M; Wilding G; Cella D; Wagner L; Matin S; Kuzel TM; Sexton WJ; Wong YN; Choueiri TK; Pili R; Puzanov I; Kohli M; Stadler W; Carducci M; Coomes R; DiPaola RS Lancet; 2016 May; 387(10032):2008-16. PubMed ID: 26969090 [TBL] [Abstract][Full Text] [Related]
8. A randomized, open-label, phase 3 trial of pembrolizumab plus epacadostat versus sunitinib or pazopanib as first-line treatment for metastatic renal cell carcinoma (KEYNOTE-679/ECHO-302). Lara PN; Villanueva L; Ibanez C; Erman M; Lee JL; Heinrich D; Lipatov ON; Gedye C; Gokmen E; Acevedo A; Semenov A; Park SH; Gafanov RA; Kose F; Jones M; Du X; Munteanu M; Perini R; Choueiri TK; Motzer RJ BMC Cancer; 2024 Jul; 23(Suppl 1):1253. PubMed ID: 39054430 [TBL] [Abstract][Full Text] [Related]
9. The efficacy and safety of sunitinib given on an individualised schedule as first-line therapy for metastatic renal cell carcinoma: A phase 2 clinical trial. Bjarnason GA; Knox JJ; Kollmannsberger CK; Soulieres D; Ernst DS; Zalewski P; Canil CM; Winquist E; Hotte SJ; North SA; Heng DYC; Macfarlane RJ; Venner PM; Kapoor A; Hansen AR; Eigl BJ; Czaykowski P; Boyd B; Wang L; Basappa NS Eur J Cancer; 2019 Feb; 108():69-77. PubMed ID: 30648632 [TBL] [Abstract][Full Text] [Related]
10. Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. Rini BI; Powles T; Atkins MB; Escudier B; McDermott DF; Suarez C; Bracarda S; Stadler WM; Donskov F; Lee JL; Hawkins R; Ravaud A; Alekseev B; Staehler M; Uemura M; De Giorgi U; Mellado B; Porta C; Melichar B; Gurney H; Bedke J; Choueiri TK; Parnis F; Khaznadar T; Thobhani A; Li S; Piault-Louis E; Frantz G; Huseni M; Schiff C; Green MC; Motzer RJ; Lancet; 2019 Jun; 393(10189):2404-2415. PubMed ID: 31079938 [TBL] [Abstract][Full Text] [Related]
11. A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial. Pal SK; Tangen C; Thompson IM; Balzer-Haas N; George DJ; Heng DYC; Shuch B; Stein M; Tretiakova M; Humphrey P; Adeniran A; Narayan V; Bjarnason GA; Vaishampayan U; Alva A; Zhang T; Cole S; Plets M; Wright J; Lara PN Lancet; 2021 Feb; 397(10275):695-703. PubMed ID: 33592176 [TBL] [Abstract][Full Text] [Related]
12. Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. Motzer RJ; Rini BI; McDermott DF; Arén Frontera O; Hammers HJ; Carducci MA; Salman P; Escudier B; Beuselinck B; Amin A; Porta C; George S; Neiman V; Bracarda S; Tykodi SS; Barthélémy P; Leibowitz-Amit R; Plimack ER; Oosting SF; Redman B; Melichar B; Powles T; Nathan P; Oudard S; Pook D; Choueiri TK; Donskov F; Grimm MO; Gurney H; Heng DYC; Kollmannsberger CK; Harrison MR; Tomita Y; Duran I; Grünwald V; McHenry MB; Mekan S; Tannir NM; Lancet Oncol; 2019 Oct; 20(10):1370-1385. PubMed ID: 31427204 [TBL] [Abstract][Full Text] [Related]
13. Safety and effectiveness of classical and alternative sunitinib dosing schedules for metastatic renal cell carcinoma: a meta-analysis. Abogunrin S; Ashaye AO; Cappelleri JC; Clair AG; Fahrbach K; Ramaswamy K; Serfass L; Srinivas S; Thomaidou D; Zanotti G Future Oncol; 2019 Jun; 15(18):2175-2190. PubMed ID: 31010323 [TBL] [Abstract][Full Text] [Related]
14. Negative Effect of Immediate Sunitinib Interruption on Survival in Patients With Metastatic Renal Cell Carcinoma. Ishiyama R; Ishihara H; Kondo T; Takagi T; Yoshida K; Iizuka J; Kobayashi H; Okumi M; Ishida H; Tanabe K In Vivo; 2019; 33(6):2153-2160. PubMed ID: 31662551 [TBL] [Abstract][Full Text] [Related]
15. Frequent dose interruptions are required for patients receiving oral kinase inhibitor therapy for advanced renal cell carcinoma. La Vine DB; Coleman TA; Davis CH; Carbonell CE; Davis WB Am J Clin Oncol; 2010 Jun; 33(3):217-20. PubMed ID: 19745694 [TBL] [Abstract][Full Text] [Related]
16. Efficacy of Savolitinib vs Sunitinib in Patients With MET-Driven Papillary Renal Cell Carcinoma: The SAVOIR Phase 3 Randomized Clinical Trial. Choueiri TK; Heng DYC; Lee JL; Cancel M; Verheijen RB; Mellemgaard A; Ottesen LH; Frigault MM; L'Hernault A; Szijgyarto Z; Signoretti S; Albiges L JAMA Oncol; 2020 Aug; 6(8):1247-1255. PubMed ID: 32469384 [TBL] [Abstract][Full Text] [Related]
17. Randomised Phase II study comparing alternating cycles of sunitinib and everolimus vs standard sequential administration in first-line metastatic renal carcinoma (SUNRISES study). Rodriguez-Vida A; Bamias A; Esteban E; Saez MI; Lopez-Brea M; Castellano D; Caballero C; Gonzalez-Larriba JL; Calvo E; Macia S; Ravaud A; Bellmunt J BJU Int; 2020 Nov; 126(5):559-567. PubMed ID: 32654362 [TBL] [Abstract][Full Text] [Related]